Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2016; 6(10):1491-1505. doi:10.7150/thno.15111 This issue Cite

Research Paper

Novel Cs-Based Upconversion Nanoparticles as Dual-Modal CT and UCL Imaging Agents for Chemo-Photothermal Synergistic Therapy

Yuxin Liu†, Luoyuan Li †, Quanwei Guo, Lu Wang, Dongdong Liu, Ziwei Wei, Jing Zhou✉

Department of Chemistry, Capital Normal University, No.105 Xi San Huan Road, Beijing 100048, P. R. China.
† These authors contribute equally in this work.

✉ Corresponding author: jingzhouedu.cn (J. Zhou)

Citation:
Liu Y, Li L, Guo Q, Wang L, Liu D, Wei Z, Zhou J. Novel Cs-Based Upconversion Nanoparticles as Dual-Modal CT and UCL Imaging Agents for Chemo-Photothermal Synergistic Therapy. Theranostics 2016; 6(10):1491-1505. doi:10.7150/thno.15111. https://www.thno.org/v06p1491.htm
Other styles

File import instruction

Abstract

Graphic abstract

Lanthanide-based contrast agents have attracted increasing attention for their unique properties and potential applications in cancer theranostics. To date, many of these agents have been studied extensively in cells and small animal models. However, performance of these theranostic nanoparticles requires further improvement. In this study, a novel CsLu2F7:Yb,Er,Tm-based visual therapeutic platform was developed for imaging-guided synergistic cancer therapy. Due to the presence of the heavy alkali metal Cesium (Cs) in host lattice, the nanoplatform can provide a higher resolution X-ray CT imaging than many other reported lanthanide-based CT contrast agents. Furthermore, by using the targeted RGD motif, chemotherapy drug alpha-tocopheryl succinate (α-TOS), and photothermal coupling agent ICG, this nanoplatform simultaneously provides multifunctional imaging and targeted synergistic therapy. To demonstrate the theranostic performance of this novel nanoplatform in vivo, visual diagnosis in the small animal model was realized by UCL/CT imaging which was further integrated with targeted chemo-photothermal synergistic therapy. These results provided evidence for the successful construction of a novel lanthanide-based nanoplatform coupled with multimodal imaging diagnosis and potential application in synergistic cancer theranostics.

Keywords: CsLu2F7, UCL, CT, chemotherapy, photothermal therapy, synergistic therapy

Citation styles

APA
Liu, Y., Li, L., Guo, Q., Wang, L., Liu, D., Wei, Z., Zhou, J. (2016). Novel Cs-Based Upconversion Nanoparticles as Dual-Modal CT and UCL Imaging Agents for Chemo-Photothermal Synergistic Therapy. Theranostics, 6(10), 1491-1505. https://doi.org/10.7150/thno.15111.

ACS
Liu, Y.; Li, L.; Guo, Q.; Wang, L.; Liu, D.; Wei, Z.; Zhou, J. Novel Cs-Based Upconversion Nanoparticles as Dual-Modal CT and UCL Imaging Agents for Chemo-Photothermal Synergistic Therapy. Theranostics 2016, 6 (10), 1491-1505. DOI: 10.7150/thno.15111.

NLM
Liu Y, Li L, Guo Q, Wang L, Liu D, Wei Z, Zhou J. Novel Cs-Based Upconversion Nanoparticles as Dual-Modal CT and UCL Imaging Agents for Chemo-Photothermal Synergistic Therapy. Theranostics 2016; 6(10):1491-1505. doi:10.7150/thno.15111. https://www.thno.org/v06p1491.htm

CSE
Liu Y, Li L, Guo Q, Wang L, Liu D, Wei Z, Zhou J. 2016. Novel Cs-Based Upconversion Nanoparticles as Dual-Modal CT and UCL Imaging Agents for Chemo-Photothermal Synergistic Therapy. Theranostics. 6(10):1491-1505.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use